Ge Long Hui·2025-08-20 11:54Group 1 - Rongchang Biopharma (688331.SH) has entered into an agreement with Santen Pharmaceutical Co., Ltd.'s wholly-owned subsidiary, Santen China, to grant a paid license for its proprietary RC28-E injection [1] - Santen China will obtain exclusive rights for the development, production, and commercialization of RC28-E in Greater China, South Korea, Thailand, Vietnam, Singapore, the Philippines, Indonesia, and Malaysia, while Rongchang Biopharma retains global exclusive rights outside these regions [1] - Rongchang Biopharma will receive a non-refundable and non-offsettable upfront payment of 250 million RMB, with potential milestone payments of up to 520 million RMB for development and regulatory milestones, and up to 525 million RMB for sales milestones [1] Group 2 - Santen China is responsible for the business development of Santen Pharmaceutical in the Chinese market [2] - Santen Pharmaceutical, established over 130 years ago, specializes in ophthalmic pharmaceuticals and is a leader in the global ophthalmic market, focusing on prescription drugs, over-the-counter products, medical devices, and innovative service models [2] - The company's product range includes treatments for glaucoma, dry eye, myopia control, and retinal diseases [2]